The quest for small-molecule cancer immunotherapeutics
If you are working in computer-aided drug design, this in silico talk is for you: SIB Senior Research Scientist Ute Röhrig takes you on a journey to push the boundaries of knowledge around IDO1 and its role in immunotherapy resistance. IDO1’s promising properties caused an initial ‘gold rush’ from the pharma sector in search of inhibitors. But the effect of IDO1 inhibition proved to be complex in the clinics, and the pharma’s interest faded. The paper Ute and her colleagues recently published in the Journal of Medicinal Chemistry leverages 15 years of research on the mechanism and inhibition of IDO1: in this talk you will learn about the tools and approaches they used, applicable to any other drug target, but also what it takes to prepare for a renaissance of IDO1 as a target in cancer or other pathologies.
About the in silico talks series – The latest in bioinformatics by SIB Scientists
The in silico talks online series aims to inform bioinformaticians, life scientists and clinicians about the latest advances led by SIB Scientists on a wide range of topics in bioinformatics methods, research and resources. Stay abreast of the latest developments, get exclusive insights into recent papers, and discover how these advances might help you in your work or research, by subscribing to the in silico talks mailing list.
Röhrig U et al. Structure and Plasticity of Indoleamine 2,3-Dioxygenase 1 (IDO1). J. Med. Chem. 2021, 64, 24, 17690–17705.